^
Association details:
| Biomarker: | FGFR2 amplification |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Iclusig (ponatinib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models
Excerpt:
We next evaluated the activity of ponatinib in ER-negative breast cancer cell lines, SUM 52PE and MFM-223, that overexpress FGFR2 due to genomic amplification (8). Ponatinib inhibited growth of SUM 52PE and MFM-223 cells with GI50 values of 14 and 69 nmol/L, respectively (Fig. 5B).
DOI:
10.1158/1535-7163.MCT-11-0450
